BA   184.21 (+6.38%)
BA   184.21 (+6.38%)
BA   184.21 (+6.38%)
BA   184.21 (+6.38%)
Log in

NASDAQ:MEDPMedpace Stock Price, Forecast & News

$88.88
-1.39 (-1.54 %)
(As of 06/4/2020 12:32 PM ET)
Add
Compare
Today's Range
$88.31
Now: $88.88
$90.77
50-Day Range
$76.17
MA: $85.33
$95.68
52-Week Range
$53.10
Now: $88.88
$109.09
Volume4,288 shs
Average Volume264,604 shs
Market Capitalization$3.14 billion
P/E Ratio30.65
Dividend YieldN/A
Beta1.22
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Read More
Medpace logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$860.97 million
Cash Flow$3.73 per share
Book Value$20.16 per share

Profitability

Net Income$100.44 million

Miscellaneous

Employees3,500
Market Cap$3.14 billion
Next Earnings Date7/27/2020 (Confirmed)
OptionableOptionable

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

Medpace (NASDAQ:MEDP) Frequently Asked Questions

How has Medpace's stock been impacted by COVID-19 (Coronavirus)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 6.0% and is now trading at $88.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Medpace?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medpace.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 27th 2020. View our earnings forecast for Medpace.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Monday, July 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) issued its quarterly earnings results on Tuesday, April, 28th. The company reported $0.76 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.77 by $0.01. The company had revenue of $230.88 million for the quarter, compared to the consensus estimate of $226.23 million. Medpace had a return on equity of 16.96% and a net margin of 12.37%. Medpace's revenue was up 15.0% on a year-over-year basis. During the same period last year, the business posted $0.64 earnings per share. View Medpace's earnings history.

What price target have analysts set for MEDP?

5 analysts have issued 12 month target prices for Medpace's shares. Their forecasts range from $75.00 to $99.00. On average, they expect Medpace's stock price to reach $86.50 in the next twelve months. This suggests that the stock has a possible downside of 2.4%. View analysts' price targets for Medpace.

Has Medpace been receiving favorable news coverage?

Media coverage about MEDP stock has trended very negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medpace earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutMedpace.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Baidu (BIDU), Alibaba Group (BABA), Square (SQ), JD.Com (JD), Trade Desk (TTD), Adobe (ADBE), Alteryx (AYX) and Cisco Systems (CSCO).

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.64%), Wasatch Advisors Inc. (6.48%), Pendal Group Ltd (3.09%), State Street Corp (2.43%), Fuller & Thaler Asset Management Inc. (2.05%) and Invesco Ltd. (1.60%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View institutional ownership trends for Medpace.

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Federated Hermes Inc., Pendal Group Ltd, BlackRock Inc., MERIAN GLOBAL INVESTORS UK Ltd, and Acadian Asset Management LLC. Company insiders that have sold Medpace company stock in the last year include Jesse J Geiger, and Stephen P Ewald. View insider buying and selling activity for Medpace.

Which major investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Fuller & Thaler Asset Management Inc., Matarin Capital Management LLC, Franklin Resources Inc., Ranger Investment Management L.P., Meritage Portfolio Management, State Street Corp, and Eagle Asset Management Inc.. View insider buying and selling activity for Medpace.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $88.66.

How big of a company is Medpace?

Medpace has a market capitalization of $3.14 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.